피부암 진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 검사 유형별, 최종 용도별, 지역별, 전망과 예측(2024-2031년)

The Global Skin Cancer Diagnostics Market size is expected to reach $12.8 billion by 2031, rising at a market growth of 5.3% CAGR during the forecast period.

A combination of high skin cancer prevalence, advanced healthcare infrastructure, and strong government support drives the market in this region. Skin cancer, particularly non-melanoma and melanoma is highly prevalent in the United States, with millions of cases diagnosed annually. This widespread incidence necessitates extensive diagnostic services. Advanced healthcare systems in North America, particularly in the United States and Canada, are equipped with state-of-the-art diagnostic tools such as dermatoscopes, confocal microscopes, and AI-enhanced imaging systems, which enhance diagnostic accuracy and efficiency. Thus, the North America region acquired 37% revenue share in the market 2023.

The proportion of people diagnosed with melanoma around the world has been gradually climbing, which has led to a rise in the demand for cutting-edge diagnostic tools and technology. Globally, 132,000 melanoma skin cancers and 2 to 3 million non-melanoma skin cancers are diagnosed annually, according to the World Health Organization (WHO).

Additionally, it is projected that the incidence of skin cancer will increase, particularly among those who are 50 years of age or older, as the global population advances in age. Consequently, the demand for more comprehensive diagnostic methods and healthcare services will increase.

However, advanced equipment such as dermatoscopes, confocal microscopes, and sophisticated imaging systems represent cutting-edge technology for accurate and early skin cancer detection. However, the development and manufacturing of these tools involve substantial investment, which is reflected in their market prices.

Type Outlook

Based on cancer type, the market is characterized into melanoma and non-melanoma. The non-melanoma segment garnered 72% revenue share in the market in 2023. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), the two most prevalent forms of skin cancer, are the primary factors driving the segment.

Test Type Outlook

On the basis of test type, the market is classified into dermatoscopy, skin biopsy, lymph node biopsy, imaging tests, and others. The imaging tests segment recorded 27% revenue share in the market in 2023.

End-use Outlook

By end-use, the market is divided into hospital & clinics, laboratories, and others. The hospital & clinics segment witnessed 51% revenue share in the market in 2023. Patients who require medical attention for skin issues, including potential skin cancer, are served by hospitals and clinics as their primary sites of care.

Reginal Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment acquired 23% revenue share in the skin cancer diagnostics market in 2023. Countries like Australia face high skin cancer rates due to significant UV exposure while emerging markets such as China, India, and Japan are witnessing increasing skin cancer cases.

List of Key Companies Profiled

• Castle Biosciences, Inc.
• Bausch Health Companies, Inc. (DermTech, Inc.)
• Canfield Scientific, Inc.
• DermaSensor, Inc.
• F. Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Quest Diagnostics Incorporated.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)
• FotoFinder Systems GmbH
• Veriskin Inc

Global Skin Cancer Diagnostics Market Report Segmentation

By Type

• Non-Melanoma
• Melanoma

By Test Type

• Skin Biopsy
• Imaging Tests
• Dermatoscopy
• Lymph Node Biopsy
• Others

By End-use

• Hospital & Clinics
• Laboratories
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Skin Cancer Diagnostics Market, by Type
  • 1.4.2 Global Skin Cancer Diagnostics Market, by Test Type
  • 1.4.3 Global Skin Cancer Diagnostics Market, by End-use
  • 1.4.4 Global Skin Cancer Diagnostics Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Skin Cancer Diagnostics Market by Type

• 4.1 Global Non-Melanoma Market by Region
• 4.2 Global Melanoma Market by Region

Chapter 5. Global Skin Cancer Diagnostics Market by Test Type

• 5.1 Global Skin Biopsy Market by Region
• 5.2 Global Imaging Tests Market by Region
• 5.3 Global Dermatoscopy Market by Region
• 5.4 Global Lymph Node Biopsy Market by Region
• 5.5 Global Others Market by Region

Chapter 6. Global Skin Cancer Diagnostics Market by End-use

• 6.1 Global Hospital & Clinics Market by Region
• 6.2 Global Laboratories Market by Region
• 6.3 Global Others Market by Region

Chapter 7. Global Skin Cancer Diagnostics Market by Region

• 7.1 North America Skin Cancer Diagnostics Market
  • 7.1.1 North America Skin Cancer Diagnostics Market by Type
    • 7.1.1.1 North America Non-Melanoma Market by Country
    • 7.1.1.2 North America Melanoma Market by Country
  • 7.1.2 North America Skin Cancer Diagnostics Market by Test Type
    • 7.1.2.1 North America Skin Biopsy Market by Country
    • 7.1.2.2 North America Imaging Tests Market by Country
    • 7.1.2.3 North America Dermatoscopy Market by Country
    • 7.1.2.4 North America Lymph Node Biopsy Market by Country
    • 7.1.2.5 North America Others Market by Country
  • 7.1.3 North America Skin Cancer Diagnostics Market by End-use
    • 7.1.3.1 North America Hospital & Clinics Market by Country
    • 7.1.3.2 North America Laboratories Market by Country
    • 7.1.3.3 North America Others Market by Country
  • 7.1.4 North America Skin Cancer Diagnostics Market by Country
    • 7.1.4.1 US Skin Cancer Diagnostics Market
      • 7.1.4.1.1 US Skin Cancer Diagnostics Market by Type
      • 7.1.4.1.2 US Skin Cancer Diagnostics Market by Test Type
      • 7.1.4.1.3 US Skin Cancer Diagnostics Market by End-use
    • 7.1.4.2 Canada Skin Cancer Diagnostics Market
      • 7.1.4.2.1 Canada Skin Cancer Diagnostics Market by Type
      • 7.1.4.2.2 Canada Skin Cancer Diagnostics Market by Test Type
      • 7.1.4.2.3 Canada Skin Cancer Diagnostics Market by End-use
    • 7.1.4.3 Mexico Skin Cancer Diagnostics Market
      • 7.1.4.3.1 Mexico Skin Cancer Diagnostics Market by Type
      • 7.1.4.3.2 Mexico Skin Cancer Diagnostics Market by Test Type
      • 7.1.4.3.3 Mexico Skin Cancer Diagnostics Market by End-use
    • 7.1.4.4 Rest of North America Skin Cancer Diagnostics Market
      • 7.1.4.4.1 Rest of North America Skin Cancer Diagnostics Market by Type
      • 7.1.4.4.2 Rest of North America Skin Cancer Diagnostics Market by Test Type
      • 7.1.4.4.3 Rest of North America Skin Cancer Diagnostics Market by End-use
• 7.2 Europe Skin Cancer Diagnostics Market
  • 7.2.1 Europe Skin Cancer Diagnostics Market by Type
    • 7.2.1.1 Europe Non-Melanoma Market by Country
    • 7.2.1.2 Europe Melanoma Market by Country
  • 7.2.2 Europe Skin Cancer Diagnostics Market by Test Type
    • 7.2.2.1 Europe Skin Biopsy Market by Country
    • 7.2.2.2 Europe Imaging Tests Market by Country
    • 7.2.2.3 Europe Dermatoscopy Market by Country
    • 7.2.2.4 Europe Lymph Node Biopsy Market by Country
    • 7.2.2.5 Europe Others Market by Country
  • 7.2.3 Europe Skin Cancer Diagnostics Market by End-use
    • 7.2.3.1 Europe Hospital & Clinics Market by Country
    • 7.2.3.2 Europe Laboratories Market by Country
    • 7.2.3.3 Europe Others Market by Country
  • 7.2.4 Europe Skin Cancer Diagnostics Market by Country
    • 7.2.4.1 Germany Skin Cancer Diagnostics Market
      • 7.2.4.1.1 Germany Skin Cancer Diagnostics Market by Type
      • 7.2.4.1.2 Germany Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.1.3 Germany Skin Cancer Diagnostics Market by End-use
    • 7.2.4.2 UK Skin Cancer Diagnostics Market
      • 7.2.4.2.1 UK Skin Cancer Diagnostics Market by Type
      • 7.2.4.2.2 UK Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.2.3 UK Skin Cancer Diagnostics Market by End-use
    • 7.2.4.3 France Skin Cancer Diagnostics Market
      • 7.2.4.3.1 France Skin Cancer Diagnostics Market by Type
      • 7.2.4.3.2 France Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.3.3 France Skin Cancer Diagnostics Market by End-use
    • 7.2.4.4 Russia Skin Cancer Diagnostics Market
      • 7.2.4.4.1 Russia Skin Cancer Diagnostics Market by Type
      • 7.2.4.4.2 Russia Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.4.3 Russia Skin Cancer Diagnostics Market by End-use
    • 7.2.4.5 Spain Skin Cancer Diagnostics Market
      • 7.2.4.5.1 Spain Skin Cancer Diagnostics Market by Type
      • 7.2.4.5.2 Spain Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.5.3 Spain Skin Cancer Diagnostics Market by End-use
    • 7.2.4.6 Italy Skin Cancer Diagnostics Market
      • 7.2.4.6.1 Italy Skin Cancer Diagnostics Market by Type
      • 7.2.4.6.2 Italy Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.6.3 Italy Skin Cancer Diagnostics Market by End-use
    • 7.2.4.7 Rest of Europe Skin Cancer Diagnostics Market
      • 7.2.4.7.1 Rest of Europe Skin Cancer Diagnostics Market by Type
      • 7.2.4.7.2 Rest of Europe Skin Cancer Diagnostics Market by Test Type
      • 7.2.4.7.3 Rest of Europe Skin Cancer Diagnostics Market by End-use
• 7.3 Asia Pacific Skin Cancer Diagnostics Market
  • 7.3.1 Asia Pacific Skin Cancer Diagnostics Market by Type
    • 7.3.1.1 Asia Pacific Non-Melanoma Market by Country
    • 7.3.1.2 Asia Pacific Melanoma Market by Country
  • 7.3.2 Asia Pacific Skin Cancer Diagnostics Market by Test Type
    • 7.3.2.1 Asia Pacific Skin Biopsy Market by Country
    • 7.3.2.2 Asia Pacific Imaging Tests Market by Country
    • 7.3.2.3 Asia Pacific Dermatoscopy Market by Country
    • 7.3.2.4 Asia Pacific Lymph Node Biopsy Market by Country
    • 7.3.2.5 Asia Pacific Others Market by Country
  • 7.3.3 Asia Pacific Skin Cancer Diagnostics Market by End-use
    • 7.3.3.1 Asia Pacific Hospital & Clinics Market by Country
    • 7.3.3.2 Asia Pacific Laboratories Market by Country
    • 7.3.3.3 Asia Pacific Others Market by Country
  • 7.3.4 Asia Pacific Skin Cancer Diagnostics Market by Country
    • 7.3.4.1 China Skin Cancer Diagnostics Market
      • 7.3.4.1.1 China Skin Cancer Diagnostics Market by Type
      • 7.3.4.1.2 China Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.1.3 China Skin Cancer Diagnostics Market by End-use
    • 7.3.4.2 Japan Skin Cancer Diagnostics Market
      • 7.3.4.2.1 Japan Skin Cancer Diagnostics Market by Type
      • 7.3.4.2.2 Japan Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.2.3 Japan Skin Cancer Diagnostics Market by End-use
    • 7.3.4.3 India Skin Cancer Diagnostics Market
      • 7.3.4.3.1 India Skin Cancer Diagnostics Market by Type
      • 7.3.4.3.2 India Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.3.3 India Skin Cancer Diagnostics Market by End-use
    • 7.3.4.4 South Korea Skin Cancer Diagnostics Market
      • 7.3.4.4.1 South Korea Skin Cancer Diagnostics Market by Type
      • 7.3.4.4.2 South Korea Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.4.3 South Korea Skin Cancer Diagnostics Market by End-use
    • 7.3.4.5 Singapore Skin Cancer Diagnostics Market
      • 7.3.4.5.1 Singapore Skin Cancer Diagnostics Market by Type
      • 7.3.4.5.2 Singapore Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.5.3 Singapore Skin Cancer Diagnostics Market by End-use
    • 7.3.4.6 Malaysia Skin Cancer Diagnostics Market
      • 7.3.4.6.1 Malaysia Skin Cancer Diagnostics Market by Type
      • 7.3.4.6.2 Malaysia Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.6.3 Malaysia Skin Cancer Diagnostics Market by End-use
    • 7.3.4.7 Rest of Asia Pacific Skin Cancer Diagnostics Market
      • 7.3.4.7.1 Rest of Asia Pacific Skin Cancer Diagnostics Market by Type
      • 7.3.4.7.2 Rest of Asia Pacific Skin Cancer Diagnostics Market by Test Type
      • 7.3.4.7.3 Rest of Asia Pacific Skin Cancer Diagnostics Market by End-use
• 7.4 LAMEA Skin Cancer Diagnostics Market
  • 7.4.1 LAMEA Skin Cancer Diagnostics Market by Type
    • 7.4.1.1 LAMEA Non-Melanoma Market by Country
    • 7.4.1.2 LAMEA Melanoma Market by Country
  • 7.4.2 LAMEA Skin Cancer Diagnostics Market by Test Type
    • 7.4.2.1 LAMEA Skin Biopsy Market by Country
    • 7.4.2.2 LAMEA Imaging Tests Market by Country
    • 7.4.2.3 LAMEA Dermatoscopy Market by Country
    • 7.4.2.4 LAMEA Lymph Node Biopsy Market by Country
    • 7.4.2.5 LAMEA Others Market by Country
  • 7.4.3 LAMEA Skin Cancer Diagnostics Market by End-use
    • 7.4.3.1 LAMEA Hospital & Clinics Market by Country
    • 7.4.3.2 LAMEA Laboratories Market by Country
    • 7.4.3.3 LAMEA Others Market by Country
  • 7.4.4 LAMEA Skin Cancer Diagnostics Market by Country
    • 7.4.4.1 Brazil Skin Cancer Diagnostics Market
      • 7.4.4.1.1 Brazil Skin Cancer Diagnostics Market by Type
      • 7.4.4.1.2 Brazil Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.1.3 Brazil Skin Cancer Diagnostics Market by End-use
    • 7.4.4.2 Argentina Skin Cancer Diagnostics Market
      • 7.4.4.2.1 Argentina Skin Cancer Diagnostics Market by Type
      • 7.4.4.2.2 Argentina Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.2.3 Argentina Skin Cancer Diagnostics Market by End-use
    • 7.4.4.3 UAE Skin Cancer Diagnostics Market
      • 7.4.4.3.1 UAE Skin Cancer Diagnostics Market by Type
      • 7.4.4.3.2 UAE Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.3.3 UAE Skin Cancer Diagnostics Market by End-use
    • 7.4.4.4 Saudi Arabia Skin Cancer Diagnostics Market
      • 7.4.4.4.1 Saudi Arabia Skin Cancer Diagnostics Market by Type
      • 7.4.4.4.2 Saudi Arabia Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.4.3 Saudi Arabia Skin Cancer Diagnostics Market by End-use
    • 7.4.4.5 South Africa Skin Cancer Diagnostics Market
      • 7.4.4.5.1 South Africa Skin Cancer Diagnostics Market by Type
      • 7.4.4.5.2 South Africa Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.5.3 South Africa Skin Cancer Diagnostics Market by End-use
    • 7.4.4.6 Nigeria Skin Cancer Diagnostics Market
      • 7.4.4.6.1 Nigeria Skin Cancer Diagnostics Market by Type
      • 7.4.4.6.2 Nigeria Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.6.3 Nigeria Skin Cancer Diagnostics Market by End-use
    • 7.4.4.7 Rest of LAMEA Skin Cancer Diagnostics Market
      • 7.4.4.7.1 Rest of LAMEA Skin Cancer Diagnostics Market by Type
      • 7.4.4.7.2 Rest of LAMEA Skin Cancer Diagnostics Market by Test Type
      • 7.4.4.7.3 Rest of LAMEA Skin Cancer Diagnostics Market by End-use

Chapter 8. Company Profiles

• 8.1 Castle Biosciences, Inc.
  • 8.1.1 Company Overview
  • 8.1.2 Financial Analysis
  • 8.1.3 Research & Development Expenses
  • 8.1.4 Recent strategies and developments:
    • 8.1.4.1 Product Launches and Product Expansions:
    • 8.1.4.2 Acquisition and Mergers:
  • 8.1.5 SWOT Analysis
• 8.2 Bausch Health Companies, Inc.(DermTech, Inc.)
  • 8.2.1 Company Overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Segmental and Regional Analysis
  • 8.2.4 Research & Development Expense
  • 8.2.5 SWOT Analysis
• 8.3 Canfield Scientific, Inc.
  • 8.3.1 Company Overview
  • 8.3.2 SWOT Analysis
• 8.4 DermaSensor, Inc.
  • 8.4.1 Company Overview
  • 8.4.2 SWOT Analysis
• 8.5 F. Hoffmann-La Roche Ltd.
  • 8.5.1 Company Overview
  • 8.5.2 Financial Analysis
  • 8.5.3 Segmental and Regional Analysis
  • 8.5.4 Research & Development Expense
  • 8.5.5 Recent strategies and developments:
    • 8.5.5.1 Partnerships, Collaborations, and Agreements:
  • 8.5.6 SWOT Analysis
• 8.6 Neogenomics, Inc.
  • 8.6.1 Company Overview
  • 8.6.2 Financial Analysis
  • 8.6.3 Segmental Analysis
  • 8.6.4 Research & Development Expenses
  • 8.6.5 SWOT Analysis
• 8.7 Quest Diagnostics Incorporated
  • 8.7.1 Company Overview
  • 8.7.2 Financial Analysis
  • 8.7.3 Segmental Analysis
  • 8.7.4 Recent strategies and developments:
    • 8.7.4.1 Partnerships, Collaborations, and Agreements:
    • 8.7.4.2 Acquisition and Mergers:
  • 8.7.5 SWOT Analysis
• 8.8 Digital Diagnostics, Inc.(3Derm Systems, Inc.)
  • 8.8.1 Company Overview
• 8.9 FotoFinder Systems GmbH
  • 8.9.1 Company Overview
  • 8.9.2 SWOT Analysis
• 8.10. VERISKIN INC.
  • 8.10.1 Company Overview
  • 8.10.2 SWOT Analysis

Chapter 9. Winning Imperatives for Skin Cancer Diagnostics Market